基于健脾为本治疗慢性萎缩性胃炎及癌前病变的研究
The Research of Chronic Atrophic Gastritis and Precancerous Lesions Based on Spleen-Strengthening Therapy
DOI: 10.12677/TCM.2020.96070, PDF,    科研立项经费支持
作者: 徐燕立：浙江大学医学院附属第一医院，浙江 杭州；朱飞叶, 徐 珊：浙江中医药大学，浙江 杭州
关键词: 慢性萎缩性胃炎；脾虚证；乐胃饮；Chronic Atrophic Gastritis； Syndrome of Spleen Deficiency； Leweiyin
摘要: 慢性萎缩性胃炎是以胃黏膜腺体萎缩为主要特征的常见消化系统疾病，常伴有胃黏膜肠上皮化生和异型增生，是胃癌前疾病之一。中医药在治疗胃癌前疾病方面具有明显的特色与优势。我们认为，脾虚证在慢性萎缩性胃炎及癌前疾病中极为常见，这一病机特点也是疾病发展与转归的关键所在。本文旨在介绍本研究团队基于健脾为本治疗慢性萎缩性胃炎及癌前病变近20年的临床与实验研究，提出脾虚为本是慢性萎缩性胃炎及癌前病变的病机特点，健脾为本是治疗慢性萎缩性胃炎及癌前病变的关键。
Abstract: Chronic atrophic gastritis is a common digestive system disease characterized by gastric mucosal gland atrophy, and is often accompanied by gastric mucosa epithelium metaplasia and dysplasia. It is one of the pre-gastric cancer diseases. Traditional Chinese medicine has obvious characteristics and advantages in the treatment of pre-gastric cancer. We believe that spleen deficiency syndrome is very common in chronic atrophic gastritis and precancerous diseases, which is also the key to the development and prognosis of the disease. The aim of this paper is to introduce clinical and experimental studies of our research group in the treatment of chronic atrophic gastritis and precancerous lesions based on spleen-strengthening therapy for nearly 20 years. We suggested that the pathogenesis of chronic atrophic gastritis and precancerous lesions is spleen deficiency; therefore, strengthening the spleen is the key to treat chronic atrophic gastritis and precancerous lesions.
文章引用：徐燕立, 朱飞叶, 徐珊. 基于健脾为本治疗慢性萎缩性胃炎及癌前病变的研究[J]. 中医学, 2020, 9(6): 463-467. https://doi.org/10.12677/TCM.2020.96070

参考文献

[1] Testino, G. (2004) Gastric Preneoplastic Changes. Recenti Progressi in Medicina, 95, 239-244.
[2] 徐珊, 石君杰, 杨季国, 等. 慢性胃炎脾气虚证与胃粘膜细胞凋亡调控基因的相关性研究[J]. 中医杂志, 2004, 45(8): 614-616.
[3] 姚国栋. bcl-2、bax基因与胃癌[J]. 中国肿瘤, 2003, 12(11): 656-658.
[4] 徐珊, 周嘉鹤, 王常松, 等. 慢性萎缩性胃炎大鼠胃黏膜细胞凋亡与中医证型的相关性[J]. 中医杂志, 2007, 48(6): 538-541.
[5] 徐珊, 王常松, 周嘉鹤, 等. 慢性萎缩性胃炎不同中医证型模型大鼠胃黏膜细胞增殖基因表达[J]. 中国中西医结合杂志, 2007, 27(11): 1004-1006.
[6] 蒋红艳, 杨林, 禹正杨, 等. 胃癌和癌旁组织DNA含量、细胞增殖活性的定量分析与临床意义[J]. 中国现代医学杂志, 2012, 22(9): 48-52.
[7] 朱君华, 徐珊. 乐胃饮治疗慢性萎缩性胃炎临床研究[J]. 中华中医药杂志, 2007, 22(8): 526-527.
[8] 朱飞叶, 吴晋兰, 徐珊. 乐胃饮对慢性萎缩性胃炎大鼠胃黏膜作用的扫描电镜观察[J]. 中国中医基础医学杂志, 2012, 18(3): 269-270.
[9] 吴晋兰, 杨伟莲, 朱飞叶, 等. 乐胃饮对慢性萎缩性胃炎大鼠AQP3、AQP4蛋白表达的影响[J]. 中华中医药学刊, 2012, 30(6): 1335-1336.
[10] 朱飞叶, 谢冠群, 徐珊. 乐胃饮对胃癌前病变大鼠模型自噬基因Beclin1的影响[J]. 中华中医药杂志, 2017, 32(1): 282-284.
[11] 徐燕立, 朱飞叶, 徐珊. “乐胃饮”加味方对慢性萎缩性胃炎模型鼠胃黏膜病变及相关炎症因子的作用[J]. 浙江中医杂志, 2020, 55(2): 93-94.
[12] 朱飞叶, 谢冠群, 张永生, 等. 从NF-κB和STAT3相互作用研究乐胃饮加味方对SGC-7901人胃癌细胞的影响[J]. 中国中西医结合杂志, 2017, 37(7): 232-236.
[13] 朱飞叶, 徐珊, 谢冠群. 乐胃饮加味方对胃癌前病变中NF-κB和STAT3共调控因子表达的影响[J]. 中华中医药杂志, 2018, 33(1): 350-353.